Aclaris Therapeutics reported revenue of $1.63M and net income of -$22.48M for the quarter ended Jun 2026, down 8.3% year over year. This income statement covers 48 quarters of results from Sep 2014 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2014 | Dec2014 | Mar2015 | Jun2015 | Sep2015 | Dec2015 | Mar2016 | Jun2016 | Sep2016 | Dec2016 | Mar2017 | Jun2017 | Sep2017 | Dec2017 | Mar2018 | Jun2018 | Sep2018 | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 61.23M | 61.23M | 61.74M | 66.67M | 66.68M | 66.69M | 67.21M | 70.77M | 70.82M | 70.89M | 71.25M | 71.33M | 71.42M | 77.30M | 108.27M | 108.33M | 108.34M | 120.50M | 139.65M | 139.82M | ||||||||||||||||||||||||||||
| Revenue & cost | ||||||||||||||||||||||||||||||||||||||||||||||||
| Revenue | 1.66M | 1.50M | 1.45M | 1.53M | 19.02M | 7.75M | 2.53M | 1.87M | 9.28M | 17.57M | 2.40M | 2.77M | 4.35M | 9.21M | 1.46M | 1.78M | 3.30M | 1.29M | 2.00M | 1.63M | ||||||||||||||||||||||||||||
| Gross Profit | 0.56M | 0.35M | 0.30M | 0.46M | 18.09M | 6.88M | 1.72M | 0.83M | 8.43M | 16.84M | 1.59M | 2.14M | 3.69M | 8.51M | 0.95M | 1.26M | 2.76M | 0.76M | 1.60M | 1.41M | ||||||||||||||||||||||||||||
| Operating items | ||||||||||||||||||||||||||||||||||||||||||||||||
| Amortization - Intangibles | ||||||||||||||||||||||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 13.98M | 14.10M | 14.31M | 18.78M | 23.66M | 21.07M | 22.59M | 25.27M | 23.88M | 26.65M | 9.85M | 8.76M | 5.96M | 9.03M | 11.58M | 11.45M | 13.03M | 16.58M | 15.66M | 18.07M | ||||||||||||||||||||||||||||
| Selling, General & AdministrativeSG&A | 5.98M | 6.94M | 6.10M | 6.08M | 5.81M | 7.15M | 8.79M | 8.32M | 7.09M | 8.21M | 6.84M | 4.75M | 5.65M | 4.95M | 6.14M | 5.39M | 4.87M | 5.58M | 6.74M | 6.05M | ||||||||||||||||||||||||||||
| Other Operating ExpensesOther Opex | 0.90M | 2.20M | -1.20M | -3.40M | 2.20M | 7.10M | -0.80M | -1.50M | 1.70M | -26.30M | 2.80M | 0.20M | 0.80M | -1.30M | 0.30M | 1.50M | 0.10M | 0.40M | 0.30M | |||||||||||||||||||||||||||||
| Operating ExpensesOpex | 21.95M | 24.39M | 20.36M | 22.52M | 39.89M | 36.83M | 32.45M | 33.68M | 40.86M | 21.62M | 21.33M | 15.62M | 14.82M | 108.89M | 19.54M | 20.18M | 20.45M | 24.03M | 24.19M | 25.87M | ||||||||||||||||||||||||||||
| Operating IncomeOp. Inc | -20.30M | -22.89M | -18.91M | -20.99M | -20.87M | -29.08M | -29.92M | -31.82M | -31.58M | -4.05M | -18.93M | -12.85M | -10.47M | -99.67M | -18.08M | -18.41M | -17.15M | -22.73M | -22.19M | -24.24M | ||||||||||||||||||||||||||||
| EBIT | -20.30M | -22.89M | -18.91M | -20.99M | -20.87M | -29.08M | -29.92M | -31.82M | -31.58M | -4.05M | -18.93M | -12.85M | -10.47M | -99.67M | -18.08M | -18.41M | -17.15M | -22.73M | -22.19M | -24.24M | ||||||||||||||||||||||||||||
| Non-operating items | ||||||||||||||||||||||||||||||||||||||||||||||||
| Goodwill impairment chargesGoodwill Impair. | ||||||||||||||||||||||||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 2.32M | 2.19M | 1.99M | 1.87M | 1.99M | 2.10M | 2.17M | 2.02M | 1.82M | 1.63M | 1.51M | 1.76M | ||||||||||||||||||||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.85M | 0.09M | 0.12M | 0.46M | 0.92M | 1.44M | 1.76M | 2.25M | 2.32M | 2.19M | 1.99M | 1.87M | ||||||||||||||||||||||||||||||||||||
| Non Operating IncomeNon Op. Inc. | 2.32M | 2.19M | 1.99M | 1.87M | 2.88M | 3.12M | 3.00M | 2.98M | 2.54M | 2.94M | 2.37M | 2.73M | ||||||||||||||||||||||||||||||||||||
| Net income details | ||||||||||||||||||||||||||||||||||||||||||||||||
| EBT | -20.30M | -22.89M | -18.91M | -20.99M | -20.87M | -29.08M | -29.92M | -31.82M | -29.26M | -1.86M | -16.94M | -10.99M | -8.48M | -97.57M | -15.92M | -16.39M | -15.33M | -21.10M | -20.68M | -22.48M | ||||||||||||||||||||||||||||
| Profit After TaxPAT | -20.30M | -22.89M | -18.91M | -20.99M | -20.87M | -29.08M | -29.92M | -31.82M | -29.26M | -1.86M | -16.94M | -10.99M | -8.48M | -97.57M | -15.92M | -16.39M | -15.33M | -21.10M | -20.68M | -22.48M | ||||||||||||||||||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -21.15M | -22.80M | -18.91M | -20.99M | -20.87M | -29.08M | -29.92M | -31.82M | -29.26M | -1.86M | -16.94M | -10.99M | -8.48M | -97.57M | -15.92M | -16.39M | -15.33M | -21.10M | -20.68M | -22.48M | ||||||||||||||||||||||||||||
| Income from Discontinued OperationsIncome (Discontinued) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Consolidated Net IncomeConsol Net Inc. | -21.15M | -22.80M | -18.91M | -20.99M | -20.87M | -29.08M | -29.92M | -31.82M | -29.26M | -1.86M | -16.94M | -10.99M | -8.48M | -97.57M | -15.92M | -16.39M | -15.33M | -21.10M | -20.68M | -22.48M | ||||||||||||||||||||||||||||
| Income towards Parent CompanyParent Net Inc | -21.15M | -22.80M | -18.79M | -20.53M | -19.95M | -27.64M | -28.16M | -29.57M | -29.26M | -1.49M | -16.94M | -10.99M | -7.59M | -96.55M | -15.09M | -15.43M | -14.61M | -19.80M | -19.82M | -21.50M | ||||||||||||||||||||||||||||
| Preferred Dividend PaymentsPref Dividends | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net Income towards Common StockholdersNet Income | -21.15M | -22.80M | -18.79M | -20.53M | -19.95M | -27.64M | -28.16M | -29.57M | -29.26M | -1.49M | -16.94M | -10.99M | -7.59M | -96.55M | -15.09M | -15.43M | -14.61M | -19.80M | -19.82M | -21.50M | ||||||||||||||||||||||||||||
| Additional items | ||||||||||||||||||||||||||||||||||||||||||||||||
| EPS (Basic) | -0.35 | -0.40 | -0.31 | -0.31 | -0.30 | -0.42 | -0.42 | -0.42 | -0.41 | -0.02 | -0.24 | -0.15 | -0.11 | -1.25 | -0.12 | -0.13 | -0.12 | -0.16 | -0.15 | -0.15 | ||||||||||||||||||||||||||||
| EPS (Diluted) | -0.35 | -0.40 | -0.31 | -0.31 | -0.30 | -0.42 | -0.42 | -0.42 | -0.41 | -0.02 | -0.24 | -0.15 | -0.11 | -1.25 | -0.12 | -0.13 | -0.12 | -0.16 | -0.15 | -0.15 | ||||||||||||||||||||||||||||
| Shares Outstanding | 61.22M | 56.73M | 61.43M | 65.99M | 66.68M | 65.21M | 66.87M | 70.63M | 70.81M | 69.81M | 71.07M | 71.29M | 71.38M | 77.30M | 122.39M | 122.58M | 122.62M | 122.56M | 128.81M | 142.74M | ||||||||||||||||||||||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 61.22M | 56.73M | 61.43M | 65.99M | 66.68M | 65.21M | 66.87M | 70.63M | 70.81M | 69.81M | 71.07M | 71.29M | 71.38M | 77.30M | 122.39M | 122.58M | 122.62M | 122.56M | 128.81M | 142.74M | ||||||||||||||||||||||||||||
| EBITDA | -20.10M | -22.70M | -18.70M | -20.79M | -20.68M | -28.89M | -29.72M | -31.60M | -31.36M | -3.82M | -18.69M | -12.61M | -10.29M | -99.53M | -17.96M | -18.29M | -17.04M | -22.63M | -22.09M | -24.13M |
Pull Aclaris Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=ACRS&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "ACRS", "statement": "IS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=ACRS&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();